Sihuan and CTTQ-Akeso Team up to Test AXL Inhibitor and PD-1 in Solid Tumors
publication date: Jun 2, 2022
Sihuan Pharma and CTTQ-Akeso (Shanghai) Biomed will cooperate to test Sihuan’s AXL inhibitor paired with CTTQ-Akeso’s anti-PD-1 in patients with solid tumors. Xuanzhu Biopharm, the novel drug subsidiary of Sihuan, has already been approved to start China trials of its AXL inhibitor in advanced solid tumors and hematological malignancies. CTTQ-Akeso was approved to launch its PD-1 (penpulimab), a product co-developed by Sino Bio and Akeso, as a third-line therapy for Hodgkin’s lymphoma. The companies plan to test the combination in patients with non-small cell lung cancer. More details....
Stock Symbol: (HK: 0460)
Share this with colleagues:
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.